NCT03555994View on ClinicalTrials.gov

A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

May 31, 2018

Primary Completion Date

April 14, 2021

Study Completion Date

April 14, 2021

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

MEDI0382

MEDI0382 administered subcutaneously

DRUG

Placebo

Placebo administered subcutaneously

DRUG

Liraglutide

Liraglutide administered subcutaneously

Trial Locations (3)

6229 ER

Research Site, Maastricht

752 37

Research Site, Uppsala

NG7 2UH

Research Site, Nottingham

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY

NCT03555994 - A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. | Biotech Hunter | Biotech Hunter